Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer

Programmed death ligand 1 (PD‐L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD‐L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory‐developed tests (LDTs) at 10 German testing sites.

[1]  C. Copie-Bergman,et al.  Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[2]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[3]  R. Røge,et al.  Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3 , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  D. Rimm,et al.  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.

[5]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[7]  C. Boeckx,et al.  Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system , 2017, Histopathology.

[8]  D. Rimm,et al.  Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.

[9]  S. Lantuejoul,et al.  PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC , 2017 .

[10]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[12]  M. Tiemann,et al.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.

[13]  R. Booton,et al.  PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation , 2016, Histopathology.

[14]  Antoni Ribas,et al.  The “cancer immunogram” , 2016, Science.

[15]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[16]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[17]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[18]  L. Zitvogel,et al.  Microbiome and Anticancer Immunosurveillance , 2016, Cell.

[19]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[20]  Jorge Sabbaga,et al.  Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.

[21]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[22]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[23]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[24]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Ruifrok,et al.  Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.